Central Nervous System Agents
"Central Nervous System Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
| Descriptor ID |
D002491
|
| MeSH Number(s) |
D27.505.954.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Agents".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Agents".
This graph shows the total number of publications written about "Central Nervous System Agents" by people in this website by year, and whether "Central Nervous System Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice. Eur J Pharm Sci. 2023 Feb 01; 181:106358.
-
Predictors of CNS-Active Medication Use and Polypharmacy Among Homebound Older Adults With Depression. Psychiatr Serv. 2020 08 01; 71(8):847-850.
-
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
-
Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia. Neurodegener Dis Manag. 2018 08; 8(4):233-242.
-
Evaluation and Management of Children With Acute Mental Health or Behavioral Problems. Part II: Recognition of Clinically Challenging Mental Health Related Conditions Presenting With Medical or Uncertain Symptoms. Pediatrics. 2016 09; 138(3).
-
Cutaneous Adverse Effects of Neurologic Medications. CNS Drugs. 2016 Mar; 30(3):245-67.
-
Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs. Neuron. 2014 Nov 05; 84(3):554-63.
-
Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology. 2014 Aug; 39(9):2070-7.
-
Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010 Aug; 24(8):669-93.
-
Medication errors recovered by emergency department pharmacists. Ann Emerg Med. 2010 Jun; 55(6):513-21.